This research develops nanoscale “smart package” delivery systems for PROTAC cancer drugs. Antibody nanogel conjugates selectively target cancer cells, enter them, and release therapeutic molecules while minimizing exposure to healthy tissue. The approach improves delivery efficiency and aims to reduce the severe side effects that often limit cancer treatment.

Using a Twilight analogy, this research explains antibiotic-resistant bacteria as “vampires” protected by membranes. By crystallizing membrane proteins and analyzing them with X-ray techniques, the study reveals their structure and function. This enables precise drug design to block these proteins, potentially overcoming antibiotic resistance and targeting harmful bacteria more effectively.

This research develops targeted radiopharmaceutical therapies for HER2-positive cancers. By attaching radioactive isotopes to trastuzumab, treatment delivers precise radiation to cancer cells, overcoming drug resistance. The work includes creating practical drug kits and aims to improve cancer outcomes by replacing non-specific therapies with highly accurate, targeted interventions.

Migraine affects over a billion people, yet its cellular mechanisms remain unclear. This research studies how CGRP-blocking drugs interact with two key receptors—CGRP and AMY1—to understand why treatments help some patients but not others. The findings may guide development of more effective, targeted migraine therapies and reduce debilitating attacks.